From Wiki Weed
Jump to: navigation, search

AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9nM at CB1 and 23.2nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication, but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in synthetic cannabis blends in Japan, along with a related compound AB-PINACA which had not previously been reported.

In January 2014, AB-FUBINACA was designated as a Schedule I controlled substance in the United States.

See also